Texas MPN Workshop 2020 | MPNs as a disease spectrum: are genomics the key to one’s destiny?
Raajit Rampal
Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, gives his thoughts on classifying myeloproliferative neoplasms (MPNs) into further sub-divisions, the role of genomics and where we go from here. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Related videos
1:38 The search for better post-MPN AML treatment: decitabine and ruxolitinib
Farhad Ravandi
3:42 Novel approaches to PV and ET
Alessandro Lucchesi
5:06 New insights in the biology of myeloproliferative neoplasms
Anna Rita Migliaccio
3:19 Finding novel targets for myelofibrosis from animal models
Anna Rita Migliaccio
2:33 Spleen volume responses in fedratinib treated myelofibrosis patients
Ruben Mesa
